Parkinson’s linked to the failure of the energy system cells
An international team of researchers have identified 10 genes associated with Parkinson’s disease who are involved in the functioning of mitochondria. These are organelles present in virtually all body cells, which produce one of the largest sources of chemical energy for cells.
If confirmed by further studies, the findings, published in the journal Science, Translational Medicine, may warrant clinical trials with existing drugs (currently used to treat other diseases) that activate a key way to repair and replace damaged mitochondria, the researchers say.
Clemens Scherzer of Harvard University and his colleagues to an international consortium, compared the genes in various tissues of people with Alzheimer’s disease and healthy individuals. The expression of 10 genes was reduced in the brains of parkinsonism during the early stages of the disease. Several of these genes are regulated by a single protein, PGC-1alpha, which was at low levels in Parkinson’s disease.
This suggests, says Scherzer, that drugs activating the PGC-1alpha could prevent brain damage caused by the disease.
The diabetes drug Avandia (rosiglitazone) activates a protein essential in the circuit of PGC-1alpha but was withdrawn from the European market because of cardiovascular risks. However, the antidiabetic Actos (pioglitazone), which has not been firmly linked to the risk of heart attack, remains in use. A clinical trial to treat the disease with this drug has been approved by regulators.